Cardinal Health (NYSE:CAH) subsidiary Cordis said last Friday that it launched the Mynx Control vascular closure device intended for sealing 5-7 French femoral arterial access sites. The newly launched system is intended to reduce time to hemostasis and ambulation after diagnostic or interventional procedures, the Dublin, Ohio-based company said. The system also includes a next-generation deployment system designed to […]
Vascular
FDA issues Class I recall for Roche Diagnostics’ warfarin test strips
The FDA today issued a Class I recall for certain lots of Roche Diagnostics‘ warfarin test strips used with the CoaguCheck test meter devices. Roche voluntarily recalled the strips in September, warning that for patients and doctors who use at-home devices to monitor levels of the blood thinner, the devices may yield inaccurate results. The FDA said today […]
Reva launches Fantom Encore bioresorbable scaffold
Reva Medical (ASX:RVA) said this week that it launched its Fantom Encore bioresorbable, drug-eluting scaffold and that the first person was treated in a post-market trial of the device. The Fantom Encore product is a third-gen coronary bioresorbable scaffold featuring a thin strut profile and Reva’s Tyrocore polymer. Get the full story at our sister site, […]
Livongo launches voice-enabled cellular blood pressure monitoring system
Livongo said today that it launched its Applied Health Signals platform, which seeks to provide meaningful feedback to people living with chronic conditions using novel digital tools and artificial intelligence. As part of its newly-launched platform, the company developed a voice-enabled, at-home cellular blood pressure monitoring system and said it would provide eligible members with […]
Humacyte launches Phase II vascular trauma Humacyl vessel trial
Humacyte said yesterday it launched a U.S. Phase II trial of its Humacyl investigational human acellular vessel exploring the systems’ use for vascular replacement or reconstruction in patients with life or limb-threatening vascular trauma. The Research Triangle Park, N.C.-based company said it hopes to enroll 40 adult patients at six U.S. sites for the trial, […]
Study: Delaying thombectomy, even for minutes, can lead to lifelong consequences
Delaying endovascular thrombectomy treatment for patients with acute ischemic stroke can take time off of patient’s lives and cost hospitals extra, according to a new study reported by Medscape. Results from the study were presented by Dr. Wolfgang Kunz of Munich, Germany’s Ludwig Maximilian University during the 11th World Stroke Congress. Every hour of delay […]
LeMaitre Vascular puts up $2m for BD’s Cardial
LeMaitre Vascular (NSDQ:LMAT) said today it inked a deal to acquire Becton Dickinson‘s (NYSE:BDX) Cardial subsidiary for approximately $2.3 million (EU €2 million). The Saint-Étienne, France-based subsidiary produces knitted and woven vascular grafts, valvulotomes and surgical glue, and reported approximately $3.3 million (EU €2.9 million) in sales over the past 12 months, Burlington, Mass.-based LeMaitre said. […]
Boston Scientific CEO talks pricing pressure for drug-eluting stents
On an earnings call with analysts this week, Boston Scientific (NYSE:BSX) CEO Mike Mahoney touted the momentum of his company’s drug-eluting stent portfolio but noted that the technologies continue to face headwinds in the U.S. thanks to pricing pressure. The Mass.-based company reported third-quarter profits of $432 million, or 31¢ per share, on sales of $2.39 billion […]
FDA approves Medtronic’s Valiant Navion thoracic stent graft
Medtronic (NYSE:MDT) said today that it won FDA approval for its Valiant Navion thoracic stent graft system intended for use in the minimally invasive repair of lesions in the descending thoracic aorta. The Fridley, Minn.-based company said that the stent system is now cleared for use in procedures to repair thoracic aortic aneurysms, blunt thoracic […]
BD’s Bard updates on higher restenosis rate for LifeStream covered iliac stent
C.R. Bard (NYSE:BCR) has notified buyers of its LifeStream covered iliac stent of a higher-than-anticipated restenosis rate among patients. The field notice issued by Bard, parent company BD and Irish catheter-maker ClearStream Technologies said the restenosis rate of 0.04% exceeds the acceptable failure rate of 0.01%. An unspecified number of restenosis complaints was reported following implantation of […]
Vascular Therapies raises $12m for drug-eluting vascular access implant
Vascular Therapies has raised $12.4 million from 29 investors as part of a $21.1 million round, according to a document filed last week with the SEC. The Cresskill, N.J.-based company is developing a sirolimus-eluting collagen implant for patients with end-stage renal disease. The bioresorbable drug-delivery system is designed to keep open a portal of entry […]